2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scolari, F. Articles by Maiorca, R. Search for Related Content PubMed PubMed Citation Articles by Scolari, F. Articles by Maiorca, R.

Predictors of Renal and Patient Outcomes in Atheroembolic Renal Disease: A Prospective Study

Francesco Scolari^*, Pietro Ravani, Alessandra Pola^*, Simona Guerini^*, Roberto Zubani^*, Ezio Movilli^*, Silvana Savoldi, Fabio Malberti and Rosario Maiorca^*

*Division and Chair of Nephrology, Spedali Civili and University, Brescia, Italy; Division of Nephrology, Hospital of Cremona, Italy; and Ospedale Cattinara, Trieste, Italy.

Correspondence to Dr. Francesco Scolari, Chair and Division of Nephrology, University and Spedali Civili, P.le Spedali Civili, 1, 25125 Brescia, Italy. Phone: 39-030-3995630; Fax: 39-030-3995023;

ABSTRACT. Atheroembolic renal disease (AERD) is part of a multisystemic disease accompanied by high cardiovascular comorbidity and mortality. Interrelationships between traditional risk factors for atherosclerosis, vascular comorbidities, precipitating factors, and markers of clinical severity of the disease in determining outcome remain poorly understood. Patients with AERD presenting to a single center between 1996 and 2002 were followed-up with prospective collection of clinical and biochemical data. The major outcomes included end-stage renal disease (ESRD) and death. Ninety-five patients were identified (81 male). AERD was iatrogenic in 87%. Mean age was 71.4 yr. Twenty-three patients (24%) developed ESRD; 36 patients (37.9%) died. Cox regression analysis showed that significant independent predictors of ESRD were long-standing hypertension (hazard ratio [HR] = 1.1; P < 0.001) and preexisting chronic renal impairment (HR = 2.12; P = 0.02); use of statins was independently associated with decreased risk of ESRD (HR = 0.02; P = 0.003). Age (HR = 1.09; P = 0.009), diabetes (HR = 2.55; P = 0.034), and ESRD (HR = 2.21; P = 0.029) were independent risk factors for patient mortality; male gender was independently associated with decreased risk of death (HR = 0.27; P = 0.007). Cardiovascular comorbidities, precipitating factors, and clinical severity of AERD had no prognostic impact on renal and patient survival. It is concluded that AERD has a strong clinical impact on patient and renal survival. The study clearly shows the importance of preexisting chronic renal impairment in determining both renal and patient outcome, this latter being mediated by the development of ESRD. The protective effect of statins on the development of ESRD should be evaluated in a prospective study. E-mail: fscolar@tin.it

This article has been cited by other articles:

				K. J. Rocha-Singh, A. C. Eisenhauer, S. C. Textor, C. J. Cooper, W. A. Tan, A. H. Matsumoto, K. Rosenfield, and for Writing Group 8 Atherosclerotic Peripheral Vascular Disease Symposium II: Intervention for Renal Artery Disease Circulation, December 16, 2008; 118(25): 2873 - 2878. [Full Text] [PDF]

				E. Ritz Cardiovascular Literature--Beyond Nephrology Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 317 - 323. [Full Text] [PDF]

				F C Luft and C M Gross Commentary: Shoot the renals! Heart, December 1, 2007; 93(12): 1530 - 1532. [Abstract] [Full Text] [PDF]

				S. Ignace Jr, N. Girerd Jr, and D. Fouque Good Evidence Evaluation for Good Risk Assessment Arch Intern Med, October 22, 2007; 167(19): 2146 - 2147. [Full Text] [PDF]

				F. Scolari, P. Ravani, R. Gaggi, M. Santostefano, C. Rollino, N. Stabellini, L. Colla, B. F. Viola, P. Maiorca, C. Venturelli, et al. The Challenge of Diagnosing Atheroembolic Renal Disease: Clinical Features and Prognostic Factors Circulation, July 17, 2007; 116(3): 298 - 304. [Abstract] [Full Text] [PDF]

				K. R. Polu and M. Wolf Needle in a Haystack N. Engl. J. Med., January 5, 2006; 354(1): 68 - 73. [Full Text] [PDF]

				Y. P. Liew and J. R Bartholomew Atheromatous embolization Vascular Medicine, November 1, 2005; 10(4): 309 - 326. [Abstract] [PDF]

				M. Tonelli, C. Isles, T. Craven, A. Tonkin, M. A. Pfeffer, J. Shepherd, F. M. Sacks, C. Furberg, S. M. Cobbe, J. Simes, et al. Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease Circulation, July 12, 2005; 112(2): 171 - 178. [Abstract] [Full Text] [PDF]

				R. Vanholder, Z. Massy, A. Argiles, G. Spasovski, F. Verbeke, N. Lameire, and for the European Uremic Toxin Work Group (EUTox) Chronic kidney disease as cause of cardiovascular morbidity and mortality Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1048 - 1056. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673